Diabetes Care: Association of Baseline HbA1c with Cardiovascular and Renal Outcomes

Current guidelines recommend prescribing sodium-glucose symporter 1 (SGLT2) inhibitors for patients with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) , regardless of HbA1c levels .

A study published in Diabetes Care, a leading journal in the field of diabetes, aims to investigate the relationship between HbA1c levels and cardiovascular and renal outcomes, and whether the benefits of dapagliflozin vary with baseline HbA1c levels

In the trial of dapagliflozin on cardiovascular events (DECLARE-TIMI58), 17,160 patients with type 2 diabetes were randomly assigned to dapagliflozin or placebo, with a median follow-up of 4.

In the general population, higher baseline HbA1c levels were associated with a higher risk of cardiovascular death or hospitalization for heart failure (HHF); major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction and ischemic stroke , and Cardiorenal outcomes (adjusted hazard ratios per 1% increase in HbA1c were 1.

CONCLUSIONS: Higher HbA1c levels were associated with higher cardiovascular and renal risk, especially in the MRF population, but regardless of baseline HbA1c, including patients with HbA1c <7%, up to The benefits of Glycine